The results of a phase I study using durvalumab (20 mg/kg every 4 weeks) plus tremelimumab (1 mg/kg) have been published in the Lancet Oncology [11] and revealed that this treatment provided manageable tolerability and anti-tumor activity, regardless of PD-L1 status. Here, CD274 is linked to neoplasm.